Actuate Therapeutics (ACTU): CEO received 237K units

237K

Derivative units

Traded

Apr 1, 2026

Filed

Apr 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

What came next

1. May 1, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On May 1, 2026, the Board of Directors (“Board”) of Actuate Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board.”
2. Jul 15, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On July 15, 2026, Actuate Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that that from June 1, 2026 to July 14, 2026, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Actuate Therapeutics

For Actuate Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ACTU page.

Other recent filings by Daniel M Schmitt, President, CEO and Director

• SEC Form 4 at Actuate Therapeutics (ACTU)Oct 29, 2026

The full history of Daniel M Schmitt, President, CEO and Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Actuate Therapeutics

• SEC Schedule 13GOct 30, 2026
• SEC Form 4Oct 29, 2026
• SEC Form 4Jan 7, 2026
• SEC Form 4Jun 30, 2025
• SEC Form 4Jun 30, 2025
• SEC Form 4Jun 30, 2025

Everything OQRO holds on this company is on its ACTU page.